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Simple Summary: Impairment of the immune-barrier system in the aged brain is manifested in 
neurodegenerative diseases, such as Alzheimer’s disease. Cerebrospinal fluid flow and drainage 
system of meningeal lymph scavenge the waste products in the brain parenchyma. Recent accumu-
lating attention to the immune system in the brain is now accompanied by the expanding 
knowledge of the breakdown mechanism of the blood-brain barrier and increased permeability of 
activated immune cells at the glymphatic system, in developing brains, and in the situation of in-
fections. These disruptions of the immune-barrier function between vasculature and brain paren-
chyma, where neurons locate, would also occur by infection of viruses or microorganisms, vascular 
injury, cerebral hemorrhage, neurological diseases, and other external factors like stress. Those ac-
tivate microglia, brain-resident immune cells, and allow the infiltration of immune cells, such as 
macrophages, neutrophils, and T cells. Aberrant immunity disrupts the functions of neurons and 
prevents the maturation of glia (e.g., oligodendrocytes and astrocytes), which may cause the emer-
gence of the highly variable psychiatric symptoms seen in schizophrenia, autism spectrum disor-
ders, Alexander disease, and developmental disorders via an abnormality of brain activities at both 
cellular and organism levels. Therefore, this hypothesis challenges the longstanding neuron-centric 
view of neurodegenerative and psychiatric diseases. 
Abstract: The lymphatic system is important for antigen presentation and immune surveillance. 
The lymphatic system in the brain was originally introduced by Giovanni Mascagni in 1787, while 
the rediscovery of it by Jonathan Kipnis and Kari Kustaa Alitalo now opens the door for a new 
interpretation of neurological diseases and therapeutic applications. The glymphatic system for the 
exchanges of cerebrospinal fluid (CSF) and interstitial fluid (ISF) is associated with the blood-brain 
barrier (BBB), which is involved in the maintenance of immune privilege and homeostasis in the 
brain. Recent notions from studies of postmortem brains and clinical studies of neurodegenerative 
diseases, infection, and cerebral hemorrhage, implied that the breakdown of those barrier systems 
and infiltration of activated immune cells disrupt the function of both neurons and glia in the pa-
renchyma (e.g., modulation of neurophysiological properties and maturation of myelination), 
which causes the abnormality in the functional connectivity of the entire brain network. Due to the 
vulnerability, such dysfunction may occur in developing brains as well as in senile or neurodegen-
erative diseases and may raise the risk of emergence of psychosis symptoms. Here, we introduce 
this hypothesis with a series of studies and cellular mechanisms. 
Keywords: meningeal lymph; lymphangiogenesis; glymphatic system; immune-cell infiltration into 
brain parenchyma; blood-brain barrier (BBB) breakdown; immune-triggered disruption of neuro-
glial physiology; emergence of psychosis 
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Lymph fluid conveys the interstitial fluid (ISF) containing liquid, electrolytes, blood 
gas for fluid homeostasis. Also, it helps to transport various antigens, activated antigen-
presenting cells, and immune effector cells for immune surveillance. The lymphatic sys-
tem has an independent circulation system that is distinct from blood vessels [1]  
(Figure 1). In a body, the lymphatic system is composed of a network of lymphatic vessels 
and lymph nodes. Essentially, lymph is a protective measure against bacterial and viral 
infections. However, the concept that the lymphatic organ exists in the brain had been 
neglected, and its functioning has not been investigated until recently [2–5]. While such 
lymphatic vasculature was originally recognized over 200 years ago by Giovanni Paolo 
Mascagni, who published “the Vasorum Lymphaticorum Corporis Humani Historia et 
Ichnographia” (Mascagni, 1787) [6,7]. Mascagni clearly described the meningeal lym-
phatic vessels and their physiological role, although it was difficult to address the physi-
ological functions for neurons, glia, and brain activity at that time. It took more than a 
hundred years after him for it to be termed the immune privilege of the brain [7]. Now, 
magnetic resonance imaging (MRI) with a gadolinium-based contrast agent unveiled the 
existence of the meningeal lymphatic vessels in human and nonhuman primates (i.e., com-
mon marmoset monkeys) [8]. The lymphatic system in the brain has received a great deal 
of attention not only because it is associated with dementia and Alzheimer’s disease (AD) 
but also due to its association with psychiatric symptoms caused by various intracerebral 
immune disorders. 




Figure 1. Anatomy of vasculature systems in human and mouse brains. Lymphatic and blood vessels in the human and 
mouse brains are shown. The cerebrospinal fluid (CSF) is produced in the choroid plexus of the ventricles. CSF circulates 
through thin lymphatic ducts in meninges. Pulsation mechanisms substantially drive the flow stream of CSF and menin-
geal lymph. We provide the whole lymphatic system in the brains, within our current knowledge, and their relationship 
to other organs, such as blood vessels and ventricles. According to Absinta et al. (2017) [8], in the human brain, the brain 
lymphatic vessels (LVs) are found in the superior sagittal sinus, straight sinus, cingulate gyrus, and middle meningeal 
artery. Meningeal LVs bilaterally run in parallel to the veins and sinuses. Additionally, LVs are found in cribriform plate 
at the initiation of the nasal lymphatics. The size of vessels is from 30 μm to 300 μm in diameter, depending on the location. 
In the marmoset brain, LVs are found in the superior sagittal sinus, and straight sinus [8]. According to Aspelund et al. 
(2015) [5], in the mouse brain, LVs are found in the rostral rhinal vein, superior sagittal sinus, transverse vein, sigmoid 
sinus, retroglenoid vein, middle meningeal artery, and pterygopalatine artery, in addition to the cribriform plate with a 
10–40 μm diameter [5]. 
Our living body has evolutionally developed the innate and acquired immune sys-
tems to protect from diseases by recognizing and killing non-self-substances such as path-
ogens, foreign substances, and abnormal cells, such as cancer. The activation of immune 
cells, including leucocytes, modulates the activity of neurons and glial-cells like microglia, 
astrocytes, and oligodendrocytes in the central nervous system (CNS) [9–11]. The healthy 
brain capillaries hold specialized shields, and they can cleverly shut down the invasion of 
bacteria, viruses, and toxic agents as pathogens for immune surveillance via the blood-
brain barrier (BBB) (Figure 2). The BBB per se selectively supplies substances required for 
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brain maintenance from blood, and conversely, excretes unnecessary metabolic wastes 
into the blood. Now, it is recognized that, in a situation of aberrant immunity in many 
neurodegenerative and psychiatric diseases, both the breakdown of the BBB and immune-
cell entry from the circulatory system to the brain parenchyma occur via the chemokine-
signaling pathways [11–15]. While blood vessels are the circulation system that provides 
the tissues with the oxygen and nutrients required for their various functions, the lym-
phatic system keeps tissue homeostasis by recycling ISF and maintaining immune sur-
veillance [1]. Therefore, the blood-lymph-circulation system in the CNS is not just an in-
nate feeding system for the selection of flows of solutes. The brain’s lymphatic drainage 
is currently recognized as having functions to maintain the water and ion homeostasis of 
the ISF, clearance of waste products, and reabsorption of macromolecules in fluids. The 
lymphatic system of the brain has a physiological function for modulating immune sur-
veillance and immune responses in the brain. Currently, the lymphatic system in the 
mouse and human brain were revealed [4,8,16]. The whole visualization of blood vessels 
by rendering brain tissue transparent [17] and a molecular atlas for the blood vascular and 
vessel-associated cells in mouse brains using vascular single-cell transcriptomics [18] are 
also available, and they are extremely helpful to expand our knowledge. Therefore, a lot 
of attention is paid to the fact that brain inflammation, lymphedema, aberrant immunity, 
hypertension, and obesity result in various alterations in the vascular and lymphatic sys-
tems, such as leakage, damage, cleavage, hypo- and hyper-plasia [19,20]. However, the 
link between the destruction of the immune system in the brain, especially in the course 
of development, to the emergence of psychiatric diseases is yet unsolved. Here, we at-
tempt to integrate the recent findings into a conceptual framework that represents the 
current understanding of the roles of the immune cells and glia within the vascular and 
lymph systems in brain dysfunction. 




Figure 2. Schematic cytoarchitecture of cortical and meningeal vasculatures. Leptomeningeal arteries vertically penetrate 
the cortical parenchyma and branch into arterioles, capillaries, and postcapillary venules, which lastly converge into cor-
tical veins. In the subarachnoid space, fibroblast-like cells and a collagen layer surround the arteries and veins. Cerebro-
spinal fluid (CSF) circulates right under the dura in the subarachnoid space. Smooth muscle cells cover the penetrating 
arteries, and pericytes are located around arterioles. Perivascular spaces that surround penetrating vessels are specifically 
called Virchow-Robin spaces, which are filled with pia-associated interstitial fluid (ISF). In capillaries, endothelial cells 
(ECs) compose the endothelium, which is coated by basement membranes (inset, enlarged images of vertical and trans-
verse sections). Around the postcapillary venules, there is another fluid space, called a perivascular space, between the 
astrocytic basement membrane (rose-pink) adjunct to endfeet of astrocytes and the endothelial-cell basement membrane 
(navy blue). This organized structure is the blood-brain barrier (BBB). Blood vessels are made up of ECs and mural cells 
on the abluminal surface of the endothelial cell layer. Adjoined ECs are joined at tight and adhesion junctions. The BBB is 
formed by ECs, pericytes embedded in the capillary basement membrane, and astrocyte endfeet that enclose the capillary 
in a sheath. Postcapillary venules terminate to veins, which exit the CNS parenchyma. In the dura mater, both meningeal 
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lymphatics (light green) and fenestrated blood vessels devoid of tight junctions lie down. Meningeal lymphatic vessels 
drain macromolecules from the CSF. Arachnoid granulations (Pacchionian granulations) are mulberry-like small protru-
sions of the arachnoid mater into the dura mater. They protrude into the dural venous sinuses and allow CSF to exit the 
subarachnoid space and to enter the bloodstream via veins (i.e., transverse sinus and sigmoid sinus), all of which terminate 
to the internal jugular vein. The glymphatic system is a pathway for the brain perfusion by CSF/ISF for the waste clearance 
(orange and blue gradient arrows). At the para-arterial vascular space between the basement membrane of smooth muscle 
cells and glia limitans, the CSF influxes into the brain parenchyma, which is coupled to a clearance mechanism for the 
removal of ISF and extracellular solutes from the interstitial compartments of the parenchyma. The water component of 
CSF crosses the astrocytic aquaporin-4 (AQP-4) water channels (expressed at the side of perivascular space of astrocyte 
endfeet), and the solutes enter the brain parenchyma via astrocytic transporters or ion-channels. Exchanged ISF passes 
through the perivenous space, driven primarily by arterial pulsation. The capillaries and basal meningeal lymphatic ves-
sels are morphologically correlated; the capillaries have a peripheral morphology against the large blood vessels, while 
the basal meningeal lymphatic vessels also have a terminal/initial morphology against the large lymph vessels. 
2. Main Text 
2.1. Vascular Lymphatic System in the Brain 
2.1.1. Brain Vasculature System 
Until recently, a conventional lymphatic vasculature system had been unowned in 
the central nervous system (CNS). Here, we would like to stress one physician in history 
had discovered a structure of lymphatic vessels in the brain [6,7]. The present (re)discov-
ery of the lymphatic network in the brain that drains waste products of tissues has im-
pressed us with the significance of the drainage system in the brain for scavenging mac-
romolecules and securing immune cells into the CNS ISF and CSF [2,4,21]. CSF is pro-
duced mainly by ependymal cells of the choroid plexus at the lateral ventricles and the 
cisterna magna: i.e., the posterior cerebellomedullary cistern, and they generate circula-
tive movement of the fluids. Ependymal cells also have a fluid–brain barrier function be-
tween ventricles and parenchyma, which is called the blood-cerebrospinal fluid barrier 
(BCSFB). Ependymal cells form the choroid plexus, and have high water and ion perme-
ability. The choroid plexus absorbs water and ions from the blood much more efficiently 
than the BBB and generates CSF in the ventricles and subarachnoid spaces (Figure 1). 
Arachnoid granulations, small protrusions of the arachnoid matter, allow CSF to pass 
from the subarachnoid space into the venous system (Figure 2). The circulation of ISF is 
driven by pulsation of arteries along the basement membrane and smooth muscles of the 
brain blood vessels, which unmyelinated nerves project. According to Kiviniemi et al. 
(2016) [22], other than cardiac pulsation (1.08Hz), they proved additional two types of 
physiological mechanisms affecting CSF/ISF pulsations: respiratory pulsation (0.37 Hz) 
and very low-frequency vasomotor pulsations (at 0.01–0.027 Hz and 0.027–0.073 Hz) [22]. 
Ciliary motility of ependymal cells is also known involved in the efficient and continuous 
maintenance of CSF flow near the ventricular surface [23]. While immune cells come to 
the brain via the blood vessels, meningeal lymphatic vessels are also capable of delivering 
immune cells to the brain. Louveau et al. (2015) showed lymphatic vessel endothelial hy-
aluronan receptor 1 (LYVE-1) positive abluminal vessels besides the dural sinuses, which 
contain the CD3e positive T cells [4]. LYVE-1 positive vessels run along the blood vessels 
covered by smooth muscles in the superior sagittal sinus of the meninges, as we discuss 
later. Thus, the brain lymphatic system has been considered to conduct extra-blood sup-
ply and its outflow [5]. Meningeal lymphatic vasculature assists in the drainage of CSF 
and allows immune cells to enter draining lymph nodes in a CC-chemokine receptor 7 
(CCR7 (i.e., CD197))-dependent manner. Two chemokines (C-C motif) ligands, CCL19 
and CCL21, have been identified for the receptor CCR7, which keeps the balance of im-
munity and tolerance in the body via regulation of naive and regulatory T cells and mi-
gration of dendritic cells (DCs) in the lymphoid organs [24–26]. 
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2.1.2. Characteristics of Meningeal Lymphatic System 
In general, in the body, the lymph is first drained into the initial lymphatic vessels 
that have both lymphatic capillaries, composed of lymphatic endothelial cells (LECs). The 
initial lymphatics have distinctive, discontinuous buttons in the endothelium, while the 
collecting vessels are covered with a continuous basement membrane and smooth muscle 
cells (SMCs). Endothelial cells in collecting vessels are an elongated shape, and they are 
connected by continuous zipper-like junctions [27]. Both types of junctions consist of pro-
teins typical of adherens junctions (AJs) and tight junctions (TJs). The lymph flow is uni-
directional by the function of intraluminal valves, which separate collecting lymphatic 
vessels to a series of functional units [27]. The high pressure of the lymph upstream of a 
valve enables lymph flow, which opens the valve, reverses flow-pushes of the leaflets 
against each other, and closes the valve as in the vasculature system [27]. Therefore, both 
the opening and closing of the valve depend on periodic changes in fluid pressure within 
collecting vessels, which are regulated by the smooth muscles via unmyelinated nerve 
fibers. 
In the meninges of the brain, there are also two types of afferent lymphatic vessels: 
initial and collecting vessels. Anatomically and functionally, these vessels are different in 
the presence or absence of surrounding SMCs and lymphatic valves. The meningeal lym-
phatic vessels along the superior sagittal sinus are devoid of SMCs, lymphatic valves, and 
capillaries [4]. In the basal part of the skull of the brain, the lymphatic valves and capillar-
ies of basal meningeal lymphatic vessels (mLVs) are revealed to locate adjacent to the sub-
arachnoid space in mice. The basal mLVs facilitate the uptake and drainage of CSF [5,16]. 
Collecting lymphatic vessels are mostly associated with zipper-like LEC junctions, α-
smooth muscle actin positive SMCs coverage, and lymphatic valves. In contrast, the basal 
mLVs possess a capillary network with loose button-like LEC junctions without SMC cov-
erage, which optimizes the uptake of fluid and macromolecules [16]. According to Chen 
et al. (2020), after subarachnoid hemorrhage, meningeal lymphatics promote the clearing 
of the extravasated erythrocytes in CSF by draining them from CSF into the cervical lymph 
nodes, while the pathology of subarachnoid hemorrhage becomes further aggravated by 
the inhibition of vascular endothelial growth factor receptor 3, VEGFR3 [28]. VEGFC (Vas-
cular endothelial growth factor-C) and VEGFD (Vascular endothelial growth factor-D) are 
the ligands of VEGFR3 tyrosine kinase. The meningeal lymphatics drain extravasated 
erythrocytes from CSF into cervical lymph nodes, and the inhibition of VEGFR3 exacer-
bates the pathology of subarachnoid hemorrhage [28]. 
Briefly, researchers use the marker proteins of the brain lymphatic vessels: LYVE-1, 
prospero homeobox protein 1 (Prox-1), PDPN (Podoplanin), VEGFR3, and chemokine (C-
C motif) ligand 21 (CCL21). It is distinguishable from the expression of a blood vessel 
marker protein: CD31 (PECAM-1, platelet endothelial cell adhesion molecule-1) [4,5,21]. 
Importantly, the basal mLVs are hot spots for the CSF macromolecule clearance, 
which are located close to midbrain reticular nuclei, periaqueductal gray, anterior and 
posterior lobules of the cerebellum. The effects of dysfunction of lymphatic vasculature 
systems would be potentially severe in such regions. For instance, the ventral tegmental 
area includes lots of dopaminergic neurons and contributes to motivational behavior, and 
thereby, major depression disorder (MDD) and bipolar disorder (BD). The midbrain close 
to the periaqueductal gray is implicated in the expression of autonomic nervous system 
activity via serotonergic neurons, which regulate the sleep/wake rhythm as well as mode 
and cognition. The cerebellum is one of the hottest regions newly known related to distinct 
psychiatric disorders: autism spectrum disorders (ASDs), schizophrenia, and mood dis-
orders [10,29–31], although the cerebellum had been considered the central area of motor 
coordination, and cerebellar abnormalities were believed to exclusively induce coordina-
tion disorder and tremor [32–34]. Therefore, the view of aberrant immune-triggered psy-
chiatric disorders should be noticed what brain regions are functionally disrupted and 
what connections of brain regions are impaired. These combinations may produce various 
phenotypes of behaviors, and perhaps, the spectrum of psychiatric symptoms. 
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2.1.3. Lymphatic Vasculogenesis 
In the development of primitive blood vessels (i.e., endothelial tube), the circulatory 
system precedes the nervous system. In the early stage of development, hemangioblasts 
and angioblasts appear in the mesoderm. Hemangioblasts have the potential to differen-
tiate into vascular endothelial cells and blood cells, while angioblasts are destined to dif-
ferentiate only into vascular endothelial cells. The phenomenon in which blood vessels 
(endothelial tubes) are formed by the differentiation of hemangioblasts into vascular en-
dothelial cells is called “vasculogenesis”. Endothelial cells become escorted by medial 
SMCs and pericytes, and perform morphological and functional differentiation into arter-
ies, capillaries, and veins [35,36]. Lymphatic vasculogenesis is known to be mediated by 
transdifferentiation of venous endothelial cells toward the lymphatic endothelial pheno-
type [19,27,37]. In the developmental stages, the mammalian lymphatic vasculature is 
thought to exclusively stem from preexisting embryonic veins. An elegant lineage tracing 
study of the lymphangiogenesis by Srinivasan et al. (2007) demonstrated the venous 
origin of the mammalian lymphatic vasculature [38]. Another study suggested a signifi-
cant contribution of non-venous-derived cells to the dermal lymphatic vasculature [39], 
although the studies of lymphatic vasculogenesis in the brain are just getting started. 
In mice, LECs in the body are first specified in the anterior cardinal vein around em-
bryonic day 9.5 (E9.5) when a subset of venous endothelial cells expresses the homeobox 
transcription factor Prox1 and the LYVE-1 [40]. The transcription factor SOX18 induces 
Prox1 expression and initiates LEC commitment in mice [40]. In vitro studies using human 
primary LEC and blood vascular endothelial cells (BECs) demonstrated SOX18 binding to 
the Prox1 promoter and showed that PROX1 confer BECs to lymphatic identity and direct 
them to LECs [40,41]. Thus, SOX18 and Prox1 constitute essential signaling for LEC dif-
ferentiation. The Prox1-interacting nuclear receptor Coup-TFII has been shown as an ear-
lier venous identity factor and regulates the expression of LEC-specific genes, such as 
neuropilin-2 [42]. In the early developmental stages, Prox1/LYVE-1–positive cells bud and 
migrate in the central veins. Subsequently, they would form the first bona fide lymphatic 
structures in regions where lymphangiogenic growth factor VEGFC expresses from the 
lateral mesoderm [27]. 
On the other hand, monocytes/macrophages have been proved to have involvement 
in lymphatic neoplasia in at least two ways: a source of VEGFC after appropriate stimu-
lation or by transdifferentiation into LECs that integrate into the growing capillaries [19]. 
According to the studies of Kerjaschki and colleagues, de novo lymphangiogenesis was 
originally found in tumor-associated macrophages [43] and in kidney transplants during 
organ rejection [44]. The transdifferentiation of bone marrow-derived CD11b+ macro-
phages to LECs was also found by another laboratory with observation under inflamed 
conditions in the corneal stromata. Further, the systemic elimination of macrophages can 
prevent lymphangiogenesis [45]. Subsequent studies indicate that the adaptive immune 
system can regulate lymphangiogenesis in lymph nodes in both positive and negative di-
rections, respectively [46,47]. More recently, in the CNS, Hsu et al. (2019) revealed that 
lymphatic vessels nearby the cribriform plate induce lymphangiogenesis in a VEGFC-
VEGFR3 dependent manner during experimental autoimmune encephalomyelitis (EAE) 
as an animal model of multiple sclerosis (MS) [48]. The lymphatic vessels of the cribriform 
plate drain both CSF and immune cells in the CNS parenchyma. Neuroinflammation-in-
duced lymphangiogenesis also promotes the drainage of CNS derived antigens that will 
proliferate antigen-specific T cells in the draining lymph nodes during EAE. In contrast, 
meningeal lymphatics did not undergo lymphangiogenesis during EAE, and authors 
claimed the distinct heterogeneity in CNS lymphatic vessel formations and consequent 
CNS immune surveillance [48]. 
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2.2. Glia-Lymphatic System (Glymphatic System) 
2.2.1. Glymphatic System 
In recent years, the glia-lymphatic system, also referred to as the glymphatic system, 
has been drawing more interest across various fields of medico-pharmaceutical neurosci-
ence. This is owing to the recent discovery of the meningeal lymphatic system being 
closely implicated in a wide spectrum of neurological pathologies, such as Alexander’s 
disease (AxD), AD, Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral 
sclerosis (ALS), epilepsy, and various psychiatric conditions such as ASDs, and schizo-
phrenia [11,49–51]. This insight has opened a new arena of tackling these conditions in 
search of potential novel cures. 
The term glymphatic system was initially invented by a team led by Maiken 
Nedergaard, owing its name to the mechanism resembling the lymphatic system, in con-
junction with glial cells [52] (Figure 2). It involves the convective flow of CSF mediated by 
abundant water channels called aquaporins; among subtypes, aquaporin-4 (AQP-4) is the 
most prevalent and relevant type in the CNS for water homeostasis [53–55]. AQP-4 chan-
nels are located most prominently on the vascular end-foot processes of astrocytes 
[2,56,57]. Astrocytes have been extensively studied in the past few decades, whereby some 
critical roles in the CNS and associated pathologies have been revealed. Astrocytes en-
compass many essential life-sustaining functions in the brain [56–59]. Some of those func-
tions pertinent to the current topic include homeostasis of ion and glucose concentrations 
in the extracellular space, neuroendocrine regulation of the blood flow via vasomodula-
tion, circadian rhythm, nutrients, as well as various immune cells and neurotransmitters 
in the CNS [52,56,57]. Astrocytes indirectly participate in the conduction of neuronal elec-
trical activities, the plasticity of presynaptic release and postsynaptic responsiveness, and 
the regulation of electric circuits of neurons by releasing molecules. Interestingly, among 
them, LIF (leukemia inhibitory factor) is known to promote the myelination of oligoden-
drocytes [60]. Furthermore, astrocytes are activated in response to insults to the CNS in 
forms such as trauma and inflammatory processes accompanied by social stressors in the 
neurodegenerative diseases [50,61]. Via these pathways, astrocytes are capable of trans-
forming themselves into a reactive state to facilitate repair and regeneration of the dam-
aged CNS by altering the expression of some of the genes such as the glial fibrillary acidic 
protein (GFAP) genes. The resulting “astrogliosis,” an abnormal increase in the number 
of astrocytes, amplifies the release of astrocytic glutamate, which eventually influences 
the outcome of neuronal integrity and cytotoxicity [50,51,56,61–64]. Astrocytes are also 
unique in a way that they have the capacity to respond to nearly all neurotransmitters 
when activated [65]. 
For decades, it has been our common understanding that the metabolic activities in 
the brain well exceed that of any other organs’. Yet the fate of its metabolic byproducts 
such as amyloid-β, α-synuclein, and tau protein, which are described as the culprit of 
many devastating neurodegenerative diseases, has been points of controversies to date 
[55,66,67]. According to recent studies by Nedergaard et al. (2013 and 2020) [68,69], much 
of the housekeeping for such metabolic wastes from the interstitial space of the CNS pa-
renchyma is carried out while our brain is in the resting state, more specifically, when the 
brain is in the non-REM sleep mode or is producing slow δ-waves in inverse proportion 
to heart rate [70–72]. 
2.2.2. Astrocytic Contribution and AQP-4 Function 
The bulk of the glymphatic systems is attributed to the functions of astrocytes; the 
aforementioned astrocytic water channel AQP-4 is the crucial mediator of the exchange of 
ISF and CSF, which overall acts much in the manner of a pseudolymphatic system, gov-
erned by circadian rhythm in the CNS [54,73,74]. Interestingly, AQP-4 channels not only 
play a critical role in the homeostasis in the CNS, but they also have a clinically significant 
supportive role in other sensory and metabolic organs [49,54,73,74]. The mean rate of CSF 
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production is 0.4 mL per minute in healthy humans and 0.2 mL per minute in patients 
with AD [75]. In rats, the CSF production rate is 1.2 to 1.5 μL per minute in adults and 
halves in the aged group [76]. Interestingly, a recent study reported variability of the brain 
BOLD (blood oxygen level-dependent) signal in patients with AD, mainly due to the car-
diovascular pulsations in the brain parenchyma [77]. The authors detected neither differ-
ences in the average cardiorespiratory rates nor the blood pressure between the control 
and AD groups [77]. Thus, the impairment of the brain vasculature system could be used 
as the biomarker for detecting AD patients. 
In a review article, Mader and Brimberg (2019) laid out that AQP-4 may be a factor 
in a number of pathologies [73]. Some of the neurodegenerative diseases such as AxD, 
AD, ALS, PD, as well as stroke, trauma, and psychiatric diseases (e.g., schizophrenia, ma-
jor depressive disorder, and ASD) are accompanied by dysfunctional AQP-4 and, thereby, 
the glymphatic system. It was claimed that there is a controversy regarding the clinical 
relevance of the astroglial AQP-4 functions in the role of water homeostasis; as it turned 
out, AQP-4 was not found to affect the barrier functions for macromolecules, nor the water 
content of the brain [11,78]. The following study by Iliff et al. (2012) [2] demonstrated that 
the fluorescence of small, but not large, molecular weight interstitial tracers were less 
spread in the AQP-4-null mouse brains than controls, suggesting the AQP-4-dependent 
interstitial solute and fluid clearance in the brain. The perivascular astroglial sheath is 
completely continuous and covering the capillary surface without gaps, and therefore, the 
AQP-4 would play a rate-limiting role in astrocytic endfeet [79]. 
It is now becoming evident that previously accepted models of CSF drainage were 
rather rigid and over-simplified, guided by conventional studies that were designed upon 
a set of assumptions due to various technical limitations [55]. Particularly, studies utiliz-
ing tracer distribution analyses were susceptible to artifacts [55]. Furthermore, unsurpris-
ingly the large periarterial spaces were not visible on fixed tissues without physiological 
pulsatile circulation. Consequently, the conclusions drawn based upon postmortem stud-
ies were hence skewed, reflecting only the non-dynamic, fractional picture of the system 
[55,80,81]. The periarterial spaces were elucidated only after high-resolution in vivo im-
aging such as dynamic contrast-enhanced MRI (DCE-MRI) and two-photon laser scan-
ning microscopy (2PLSM) became readily available [2,3,16,55,67,72,80,82–84]. DCE-MRI 
is an MRI perfusion technique that provides information pertaining to temporal perfusion 
of the system of interest with the administration of intrathecal paramagnetic contrast 
agents such as gadolinium [81,85]. 2PLSM is a fluorescence imagining technique based 
upon capturing the scattering and absorption patterns of the degradation signals by long-
wavelength photons, which enables real-time dynamic analyses of a thick living tissue 
such as brain parenchyma including neurons, glia, and vasculatures [2,80,86–89]. A recent 
case report study showed the artificial opening of BBB using transcranial focused ultra-
sound in the human brain, which proved the system in humans and the persistence of 
glymphatic efflux in AD and ALS patients [90]. 
2.2.3. Potential Pathophysiology of the Glymphatic System 
As discussed earlier, the pathophysiology of those progressive neurodegenerative 
conditions such as AxD is closely attributed to dysfunctional astrocytes and impaired 
glymphatic system. In AxD, when the astrocytes are triggered likely by an inflammatory 
event, they cause the overexpression of the GFAP due to gain-of-function mutation [91–
93]. This accumulation of falsely folded GFAP eventually aggregates to become Rosenthal 
fibers, which cannot be cleared by the innate glymphatic system [94,95]. This series of 
events, in turn, further upregulates gene expression, activating and recruiting more im-
mune cells, and facilitating a cascade of a positive feedback loop [91–93]. It is therefore 
becoming increasingly evident that there is well-supported clinical relevance for explor-
ing links among astrocytes, immune cells, microglia, and the glymphatic system. 
Other evidence for the roles of the astrocytes and AQP-4 behind AD and epilepsy 
may also give more insights [96–98]. In the epileptic brain, the extracellular K+-buffering, 
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AQP-4 localization, and domain organization of astrocyte processes are disrupted in 
mouse models and human patients [96,97]. Loss of perivascular AQP-4 might be involved 
in the pathogenesis of mesial temporal lobe epilepsy (MTLE). The density of AQP-4 along 
the perivascular membrane of astrocytes endfeet was reduced by 44% in hippocampal 
CA1 of MTLE compared to non-MTLE in human samples, suggesting leading to an im-
paired water and K+-homeostasis in MTLE parenchyma [96]. In mouse models of epilepsy, 
cortical astrocytes showed morphological changes and an increase in the overlap of their 
processes [97]. Therefore, mechanisms driving the CSF homeostasis are thought to be al-
tered in epilepsy. Indeed, in contrast to AD patients, respiratory-related brain pulsations 
are increased in epilepsy patients without changes in physiological cardiorespiratory rates 
[99]. The most affected region of the brain was the upper brain stem respiratory pneumo-
taxic center, midbrain, and temporal lobes, including amygdala, hippocampus, globus 
pallidus, and putamen; almost of all of which are close to the cavernous sinus in epilepsy 
patients [99] (Figure 1). 
2.3. Infiltration of Immune Cells to Brain across Vasculature System 
2.3.1. Immune Privilege 
The existence of immune privilege had been recognized in the brain parenchyma and 
retina, even in the late 19th century [100]. The explanation of this phenomenon by Peter B 
Medawar (Medawar, 1948) [101] was that physical barriers around the immune-privi-
leged site enabled it to avoid detection from the immune system: although the allografts 
are rapidly repelled from tissues such as the skin, they are accepted when placed in certain 
other sites, particularly the brain and anterior chamber of the eye. For instance, when ex-
cessive inflammation occurs in the eye in response to infection or external stimulants, the 
eye is equipped with an automatic control mechanism that suppresses inflammation to 
avoid visual dysfunction, so-called immune privilege. Recent results have revealed that 
different mechanisms of interaction with the immune system inhere not only in the eye 
and brain but also in the pregnant uterus and reproductive organs, which were previously 
thought of as immune-privileged sites [102]. The CNS was once thought to be immune-
privileged sites that are not the target of the systemic inflammatory response or immune 
response. This was based on the observation that antigens and lymphocytes can barely 
cross the BBB for host (brain) defense and hardly elicit a cellular immune response to in-
juries and inflammation. However, the brain has been recognized to be able to initiate 
immune-mediated inflammatory responses, which contribute to the development of 
many neurodegenerative and cognitive diseases and, plausibly, other mental disorders. 
2.3.2. Glial Cell-Characteristics of the Brain and the Regulation by Immunity 
According to von Bartheld et al. (2016), the validated isotropic fractionator demon-
strates that glia:neuron ratios in the human brain is less than 1:1, although it was previ-
ously considered to be 10:1 [103]. The overall total number of neocortical neurons and glial 
cells was 49 and 65 billion in females and males, respectively, with a biological variance 
of 24% [104]. The investigation by Pelvig et al. (2008) suggested that the number of oli-
godendrocytes decreases by 27% throughout life from 18–93 years, which supports the 
idea that there is an interaction between neuronal activity and the number of oligoden-
drocytes. In fact, their results also suggest correlations between total numbers of neurons 
and oligodendrocytes, while the glia/neuron ratio over age was substantially constant 
[104]. The CNS consists of various types of cells: neurons and glia, and glial cells are sep-
arated into astrocytes, oligodendrocytes, and microglia. Below is a brief summary of those 
cell characteristics: 
Astrocytes, “star-shaped cells” named by Mihály Lenhossék, are multifunctional. By 
asymmetric cell division, astrocytes arise from radial glial cells, the precursor cells of all 
types of neurons, astrocytes, and oligodendrocytes. Astrocytes substantially maintain the 
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functional structure of the brain and regulate extracellular ion environment, BBB mainte-
nance, neurotransmitter uptake, energy supply, growth of dendrites and extension of ax-
ons, repair of neural circuits, gliotransmitter release, Ca2+ oscillation, induction of synaptic 
and non-synaptic plasticity. They show various morphological forms: star-shaped, proto-
plasmic-types in the grey matter, and fibrillary type in the white matter. Tufted astrocytes 
and Rosenthal fibers are found in a pathological brain. Astrocytes were shown to integrate 
signals from various cytokines and chemokines (including interferon-γ, interleukin 
(IL)-17, IL-1β, IL-6, IL-10, and CCL2. GFAP, vimentin, AQP-4, excitatory amino acid trans-
porter 2 (EAAT2), and S100β are the marker proteins that are expressed in those cells. 
They are also involved in metabolic processes, redox homeostasis, and brain development 
[105]. Reactive phenotypes (termed A1/A2 astrocytes, defined by upregulation of GFAP 
expression) may be toxic to neurons, releasing signals that can lead to neuronal death 
[62,63]. Bergmann glia in the cerebellum and Müller cells in the retina are astrocyte ana-
logs. 
Oligodendrocytes in the CNS produce the myelin sheath insulating neuronal axons, 
which allows for faster action potential propagation (increasing conduction velocity by at 
least 50 times [106,107]), which is intervened by the nodes of Ranvier. Local release of 
synaptic vesicles from axons promotes myelination via myelin basic protein [108]. A pre-
vious study has suggested that early social isolation results in the behavioral anomaly and 
cognitive dysfunction of mature animals that was correlated with white matter altera-
tions, demyelination, and medial prefrontal cortex (mPFC) dysfunction [109], although 
the effect might be not restricted to the mPFC. Interestingly, in mouse mPFC oligoden-
drocytes, the effects of social isolation, beginning at postnatal day 21, was prominent to 
facilitate the demyelination. Such mPFC-dependent anomaly in social and cognitive be-
haviors occur only during a critical period between postnatal weeks three and five, which 
were not reversed by reintroduction to a social environment [109]. The maturation of pro-
genitor cells to oligodendrocytes are also presumed to be suppressed by an immune chal-
lenge by activated microglia/monocytes in the early phenotype in schizophrenia [11]. 
Olig1 (Oligodendrocyte transcription factor 1), 2, and 3, myelin basic protein (MBP) is 
specifically expressed in the oligodendrocytes and used as marker proteins, whereas my-
elin proteolipid protein (PLP), sulfatide, and galactosylceramide are known as myelin 
proteins [110]. 
Microglia are the most abundant resident immune cells in the CNS and are charac-
terized by the expression of IBA1 (ionized calcium-binding adaptor molecule 1) and 
CX3C-chemokine receptor 1 (known as fractalkine receptor). They promote synapse for-
mation mediated by brain-derived neurotrophic factor BDNF [111]. Their contribution to 
neurodegenerative diseases, as well as their association with microbiota, is currently evi-
dent [112]. In contrast, their roles in chronic neuroinflammation are not entirely clarified 
yet [9]. After derived from primitive macrophages in the yolk sac, microglia colonize the 
CNS before embryonic day 9 (E9) [113], and they are alive for a long time there. In the 
periphery, macrophage populations are thought to be replenished by circulating mono-
cytes derived from multipotent hematopoietic stem cells (HSCs) of the bone marrow, alt-
hough this view has been challenged [114]. In contrast, experiments have shown that there 
is little infiltration of peripheral HSCs/monocytes/macrophages into the CNS to help 
maintain or replenish microglia under normal conditions due to the mature BBB [115–
117]. In the disease model, monocytic infiltration is observed with progression to paralytic 
stages of EAE [115]. Parenchymal microglia modulate the intrinsic excitability [10,29,118] 
and the efficacy of synaptic transmission [119] of CNS neurons. They also engulf dendritic 
spines via C1q complement signaling in the developmental and senile brain [120,121]. A 
recent study using the Confetti (‘Microfetti’) mouse model for fate mapping indicated that 
microglia renew themselves randomly and steadily throughout the healthy CNS with re-
gional differences in the rate of eight to 41 months [122]. The onset of neurodegeneration 
by injury triggers rapid clonal expansion and activation of microglial cells, while the BBB 
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remains intact in their facial nerve axotomy [122]. The altered microglial network gradu-
ally returns to a steady-state cell density without macrophage emigration, which restores 
the CNS to a non-activated state [122]. Further, the transcriptomic analysis gives us im-
portant notions about microglia in the developmental program of gene expression pat-
terns and chromatin dynamics [123], regional heterogeneity of gene profile [124,125], dif-
ferent renewal rate [122], and disease conditions, e.g., AD, glioma, and MS [126–129]. 
Non-microglia resident myeloid cells, bone-marrow-cell lineage, including peri-
vascular, choroid plexus, and meningeal macrophages, and DCs also exist in the healthy 
and mature CNS parenchyma. Non-parenchymal meningeal and perivascular macro-
phages are of embryonic origin, i.e., ontogenetically related to microglia. In contrast, the 
choroid plexus macrophages are bone marrow-derived [9]. Myeloid cells are composed of 
different cell subsets, including DCs, macrophages, and monocytes. Microglia are the tis-
sue-resident macrophages of the CNS parenchyma, which is distinct from most other mac-
rophages. DCs and macrophages present antigen to infiltrating T cells in neuroinflamma-
tory diseases. In the conditions of brain inflammation, tissue-invading monocytes are in-
flammatory DCs or monocyte-derived DCs/macrophages (Figure 3). Once inflammation 
commences, these cells are the major cell-type that presents antigen to infiltrating T cells 
in diseases like EAE. They disappear once the inflammation resolves [9]. 




Figure 3. Breakdown of the central nervous system (CNS) vasculatures during inflammation. The schema of breakdown 
of the blood vasculatures and glia limitans. The disruption of the blood-brain barrier (BBB) and immune-cell permeation 
in the brain parenchyma are shown. Here, we suppose immune-pathophysiological state in the brain upon steady-state 
immune surveillance and inflammation, caused by vascular injury and cerebral hemorrhage, infection of viruses or mi-
croorganisms, neurological diseases, and other external factors. In the inflammatory condition, perivascular macrophages 
(PVMs) respond to cytokines, such as angiopoietin 2, macrophage colony-stimulating factor-1, and CXC chemokine ligand 
12 (CXCL12). PVMs detach from capillaries and reduce their release of pigment epithelium-derived factor (PEDF), which 
destabilizes the tight junctions between blood vessel endothelial cells and increases vascular permeability. PVMs receive 
circulating immune complexes through Fcγ receptor IV (FcγRIV), which induces inflammation, recruitment of monocytes, 
and neutrophils into the interstitium [130]. During inflammation in the parenchyma, T cells infiltrate into parenchyma 
and white matter, and they release interferon-γ [131–133]. APOE4 is also implicated in the disruption of the BBB by stim-
ulating a pathway: proinflammatory cyclophilin-A (CypA)—nuclear factor κB (NFκB)—matrix metalloproteinase 9 
(MMP-9) in pericytes in AD brains [134]. Mural cells and other leucocytes (e.g., dendritic cells and B cells) are omitted 
from the figure. The subfamily of T cells: helper, killer, effector, and regulatory T cells is not subdivided. 
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2.3.3. Infiltration of Immune Cells to Brain Parenchyma 
In healthy brains, immune cells in the brain are known limited to infiltration into 
parenchyma because of the existence of the BBB. In principle, immune cells, including 
DCs and T cells, actively migrate from tissues to draining lymph nodes and are then re-
turned to the blood circulation via the lymphatic vasculature for the purpose of immune 
surveillance [14]. LECs release extracellular chemokines to guide the migration of immune 
cells. Because of the lack of sufficient studies in the CNS, here, we mainly discuss the pe-
ripheral tissues. The tissue LECs are known to release CCL21, the signaling of which en-
ables DCs and T cells to enter the lymphatic vasculature via chemokine receptor type 7 
(CCR7) [135–138]. Under inflammatory conditions, tissue LECs also produce chemokine 
(C-X3-C motif) ligand 1 (CX3CL1) and chemokine (C-X-C motif) ligand 12 (CXCL12). 
CX3CL1 and CXCL12 facilitate the migration of DCs on the lymphatic vasculature via 
their receptors CX3CR1 and CXCR4, respectively [14,139]. In the CNS, CX3CR1 is the frac-
talkine receptor and is expressed on the surface of both microglia and macrophages in 
CNS. CX3CL1/CX3CR1 axis leads activated microglia in damaging oligodendrocytes, and 
thus the impairment of oligodendrocytes and white matter injury [140]. A recent report 
indicates that tissue LECs release exosome-rich endothelial vesicles, including a number 
of inflammatory cytokines in human chronic inflammatory diseases [141]. The secretion 
of exosome-rich endothelial vesicles results in the exploratory migration of immune cells 
and promotes directional migration of CX3CR1-expressing cells [141]. Intercellular adhe-
sion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin 
are also expressed in the LECs. They are involved in the adhesion and entry of the immune 
cells in dermal tissues and thus, accelerate the immune responses [14,142,143]. Johnson et 
al. (2017) unveiled that the endothelial hyaluronan receptor LYVE-1 is essential for DC-
trafficking. While DCs are docked to the basolateral surface of lymphatic vessels, the mi-
gration of DCs to the lumen occurs through hyaluronan-mediated interactions with 
LYVE-1 [144]. Further experiments regarding molecular mechanisms of immune-cell in-
filtration in the brain should expand our knowledge. 
Of note, in the lymphatic node, subcapsular sinus macrophages are yolk-sac-derived 
in the embryo and are maintained by colony-stimulating factor-1 produced by LECs in 
lymph nodes. When pathogen induces transient deletion of bone marrow-derived macro-
phages, they restore the subcapsular sinus macrophage network [145]. In contrast, in the 
CNS, microglia renew themselves under steady-state conditions, while they replenish 
through the region-specific clonal expansion after a pathological condition [117,122]. 
Severe inflammation in the brain induces damage to blood vessels, glymphatic sys-
tem, and will cause neurodegeneration [9] (Figure 3). Severe inflammation of the brain 
can result in angiopathy, i.e., the necrotic activity of tissues, capillaries, and lymph vessels. 
Damages of blood vessels in the brain are the most popular in strokes (e.g., cerebral and 
cerebellar infarction, micro hemorrhage that ruptures blood vessels or capillaries in the 
brain, and subarachnoid hemorrhage), but at a microscopic level, damaged vessels/capil-
laries and the disruption of lymphatic vessels in the brain should be related to neurologi-
cal and neurodegenerative diseases. BBB breakdown is one of the most critical concepts 
to interpret the emergence of cognitive and neurodegenerative diseases in the senile brain. 
As inferred from the mouse EAE model, the CNS inflammation and disruption of the bar-
rier structure can occur in BBB breakdown in humans [15]. Damage to the BBB in AD is 
observed by the post-mortem human brain, while it is important to know when the BBB 
breakdown occurs. Current advanced MRI scanning and the direct-current electroenceph-
alography enable the clinical diagnostic test to detect such BBB breakdowns [83,84,146]. 
2.3.4. The Structure and Dysfunction of the BBB 
Endothelial cells of capillaries are physically connected with each other through the 
TJ, AJ, and gap junction proteins (Figure 2). Endothelial TJ and AJ proteins themselves 
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constitute the physical barrier of the BBB, preventing entry of leukocyte adhesion mole-
cules, non-selective fenestrae, pinocytosis, and bulk-flow transcytosis [12,13] (Figure 3). 
The endothelium allows the rapid free diffusion of oxygen from the blood to the brain 
parenchyma and carbon dioxide to blood, which retains brain metabolism and adequate 
pH levels in the ISF and parenchymal cells. Only small lipophilic molecules (e.g., hor-
mones) and drugs with a molecular weight of <400 Da and form less than eight total hy-
drogen bonds can cross the BBB [147–149]. It has been noted that 98% of small-molecule 
drugs fail in clinical trials due to less BBB permeability. Only limited opiates, anxiolytics 
(e.g., benzodiazepines), antipsychotics (e.g., chlorpromazine), and anti-dementia drugs 
(e.g., donepezil, memantine, and tacrine) can cross the BBB; thus, the efficacy of such drug 
treatment is limited [148,150]. It is worth mentioning that such a poor parenchymal uptake 
of agents from the CSF via BBB and glymphatic fluid transport are now overcome by the 
transcranial ultrasound [151,152]. Ultrasound protocol significantly improves the brain 
parenchymal uptake of drugs and antibodies (i.e., by around four times in case of 1 kDa 
MRI tracer signals) via intrathecal administration [151]. 
Pericytes are derived from the neural crest and are integrated into the endothelial 
and astrocyte functions at the neurovascular unit, and they regulate the BBB [153]. Peri-
cytes appear to form a continuum from arteriole to venule and share a basement mem-
brane with endothelial cells. Direct contacts of pericytes with endothelium are via N-cad-
herin and connexins [154]. They are also implicated in the angiogenesis and microvascular 
stability [154] and phagocytosing toxic metabolites [155]. According to Zhao et al. (2015) 
[13], pericyte degeneration and injury occur in many neurological diseases, including AD 
[156,157], mild dementia [83], ALS [158], and stroke [159]. 
The process of signaling between astrocytes and pericytes has been shown to deteri-
orate the integrity of the BBB. Studies of transgenic apolipoprotein E (APOE) mice have 
shown that APOE4, a major genetic risk factor for AD, leads to disruption of BBB integrity 
by activating a pathway: proinflammatory cyclophilin-A (CypA)—nuclear factor κB 
(NFκB)—matrix metalloproteinase 9 (MMP-9) in pericytes [134]. This pathway leads to 
degradation of the basement membrane and TJ proteins, resulting in chronic BBB break-
down, neuronal dysfunction, and secondary neurodegenerative changes [160]. In con-
trast, APOE3 but not APOE4 binds to the low-density lipoprotein receptor-related protein 
1 (LRP1) in pericytes, which suppresses the CypA—NFκB—MMP-9 pathway [160]. 
Chronic systemic inflammation is the result of the chronic activation of the innate 
immune system, mediated by their release of pro-inflammatory cytokines (Figure 4). Ex-
perimental studies have indicated that systemic inflammation in preterm infants can alter 
the maturation of the developing brains and the behaviors of grown animals. The major 
proinflammatory cytokines responsible for early responses are IL-1β, IL-6, and tumor ne-
crosis factor-alpha (TNF-α). Microglial TNF-α induces long-term potentiation (LTP) of in-
trinsic excitability of cerebellar Purkinje neurons [118], although the effect is brain region- 
and cell type-dependent. TNF-α also modulates the synaptic efficacy [118,161] and gli-
otransmitter release [162]. IL-1β prevents the LTP induction of population spikes in the 
hippocampal CA1 [163], although inhibition of IL-1β prevents its maintenance [164]. Mice 
exposed to IL-1β had a long-lasting impairment of myelination of oligodendrocytes, 
which resulted in an increase in nonmyelinated axons while accompanied by an increased 
density of immature oligodendrocytes. These morphological abnormalities were accom-
panied by a reduction of white-matter substrate and memory deficits [165]. In a previous 
culture study, lipopolysaccharide-induced microglial activation impeded oligodendro-
cyte lineage progression, reduced the production of MBP and resulted in the death of oli-
godendrocyte progenitor cells (OPCs). Those processes involved nitric oxide-dependent 
oxidative damage and the release of TNF-α and pro-nerve growth factor [166]. Microglial 
activation by methotrexate (a chemotherapy reagent to treat cancer, autoimmune diseases, 
rheumatoid, and ectopic pregnancy) leads to persistent disruption of oligodendrocyte lin-
eage dynamics and astrocyte reactivity, resulting in the depletion of white matter OPCs, 
the persistent deficit in myelination, and the chemotherapy-related cognitive impairment 
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[167] (Figure 4). In humans who received chemotherapy, persistent depletion of oligoden-
drocyte lineage cells has been observed [167]. Recent in vivo mouse studies showed that 
the rapid perivascular microglial clustering triggered by fibrinogen leakage upon BBB 
disruption initiates the development of axonal damage in the EAE model as neuroinflam-
mation [89]. Also, systemic inflammation induces CCR5-dependent migration of brain 
resident microglia to the cerebral vasculature and microglia to phagocytose astrocytic 
endfeet during sustained inflammation, resulting in the impairment of BBB function [168]. 
 
Figure 4. A model of aberrant immunity-driven neurophysiological disruption in the emergence of psychosis symptoms. 
Infiltration of stimulated immune cells into the parenchyma causes the disruption of various physiological properties of 
neurons there. They cause a hyper- and hypo-excitability of the intrinsic membrane properties decided by the function of 
K+, Na+, and Ca2+ channels. Among them, Ca2+-activated and voltage-sensitive K+ channels (e.g., small conductance Ca2+-
activated K+ (SK) channel, and hyperpolarization-activated cyclic nucleotide-gated (HCN) channel) of neurons are shown 
to be modulated by inflammatory cytokines. Modulation of anion reversal potential is also indicated [169]. The other 
property of the postsynaptic responsiveness, decided by the expression or function of the postsynaptic ionotropic recep-
tors, also changes in response to the release of inflammatory cytokines via cytokine receptors of neurons. It is also shown 
that the aberrant activity of immune cells also modulates presynaptic transmitters' release of neurons 
[10,31,118,119,161,169–172]. Further, while oligodendrocytes make the myelin sheath of neuronal axons, which enables 
neurons to conduct action potentials efficiently to communicate with each other by insulating them, they are impaired by 
aberrant microglial activity. Demyelination and deficits in oligodendrocyte maturation cause structural hypomyelination 
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and a loss of function of the white matter. Abnormality of astrocytic differentiation also occurs, and it reduces synaptic 
coverage of astrocytes. Not only the link of disrupted glial-cell differentiation to the initial event in schizophrenia [11], we 
also propose the relevance to pervasive psychosis symptoms observed in many psychiatric disorders [11,140,166,167]. 
These neurophysiological dysfunctions occurring at the parenchymal and white-matter areas by the immune-cell infiltra-
tion and aberrant immune-cell activation, especially at the vicinity of vascular and lymphatic pathways, may produce 
abnormal functional connectivity among brain areas. Abbreviations: OL, oligodendrocyte. OPC, oligodendrocyte precur-
sor cell. 
As aforementioned, the BBB is a selective capillary barrier for solutes to enter the 
CNS. The leukocyte recruitment to the CNS and the spatial separation is conducted 
through two steps: first, leukocytes can pass across post-capillary venules into the peri-
vascular space (i.e., Virchow–Robin space) (Figure 2). Under inflammatory conditions, a 
wide range of leukocytes can enter this space, but this is not necessarily related to pathol-
ogy, as Becher et al. has pointed out [9]. Second, leukocytes progress across the glia lim-
itans, a barrier formed by astrocytic endfeet into the neuropile, which locates over the 
brain parenchyma [9] (Figures 3 and 4). Of note, the link between the immune-cellular 
infiltration and BBB dysfunction is under debate. Previous studies in mice with EAE sug-
gested that the areas of enhanced BBB permeability does not correlate with the site of 
parenchymal infiltration [173]. In fact, in a number of neurological diseases, including AD, 
prion diseases, and Acquired Immunodeficiency Syndrome (AIDS)-related dementia, it 
had been postulated that leukocytes trespass on the brain parenchyma without the BBB 
breaking down [173]. In the adult rat, injection of IL-1β induced a pronounced increase in 
the permeability of the BCSFB solely in the meninges, but not in vasculatures [174]. In 
contrast, the higher permeability of the BCSFB after inflammation in the younger brain 
(three-week-old rat) is distinct from that of the adult brain [174], which is assumed that 
neurological consequences via BBB leakage after brain inflammation is utterly different in 
the course of brain development and astrocyte maturation. The leukocyte recruitment in 
the brain would be mediated by IL-1β or de novo synthesis of additional IL-1β but not 
TNFα, depending on the regression of the tight junction proteins: occludin and ZO-1 
(Zonula occludens-1), and the injection of N-Methyl-D-aspartate (NMDA), an agonist of 
excitatory NMDA-type glutamatergic receptors, and endotoxin lipopolysaccharide (LPS) 
exacerbates the inflammatory recruitment [175,176]. Thus, those previous studies pro-
vided suggestive insight. Very recently, SARS-coronavirus 2 (SARS-CoV-2) infection was 
revealed to invade host cells via angiotensin-converting enzyme 2 (ACE2) expressed in 
the choroid plexus epithelium, causing the leakage of the brain barrier [177,178]. More 
severe damages and dysfunctions are expected in the brain regions close to the leakage. 
During steady-state immune-surveillance, leukocyte extravasation across the BBB is 
limited to few activated T lymphocytes that interact with ICAM-1 and VCAM-1 expressed 
on the lumen of vascular endothelial cells. CXCL12 expression by endothelial cells on the 
abluminal side promotes activated CD4+ T cells to penetrate the perivascular space. After 
extravasation, T cells can interact with perivascular macrophages (PVM), a heterogeneous 
group of macrophages in the perivascular space, perform crucial activities for the mainte-
nance of tight junctions between endothelial cells and limit vessel permeability, and phag-
ocytoses of pathogens to avoid inappropriate inflammation (Figure 3). In inflammatory 
diseases, PVMs respond to cytokines, such as angiopoietin 2, macrophage colony-stimu-
lating factor-1, and CXCL12. PVMs detach from capillaries and decrease their release of 
pigment epithelium-derived factor (PEDF), which results in a decrease in stability of tight 
junctions between blood vessel endothelial cells and increased vascular permeability. 
PVMs receive circulating immune complexes through Fcγ receptor IV (FcγRIV), which 
induces inflammation, recruitment of monocytes, and neutrophils into the interstitium 
[130]. During the parenchymal inflammation in AD and MS, infiltration of T cells to the 
parenchyma and the white matter is also observed [131–133]. 
Many acute and chronic inflammatory disorders in the brain involve inflammation 
of both the parenchyma and the vasculatures. Lastly, we sum up present BBB leakages of 
current studies in the condition of stroke [179], cerebral ischemia [180], sepsis [181,182], 
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Malaria [183,184], intracellular parasite [185], SARS-CoV-2 [177,178], MS [186], systemic 
lupus erythematosus (SLE) [187], and even AD [188] and EAE [89]. Other viral infections 
and parasite invasion would increase the risk [189–191]. Therefore, many brain inflamma-
tion-associated diseases may cause leukocyte infiltration and associated behavioral anom-
alies. 
2.4. Implications of the Inflammation and Immunity for the Pathophysiology of Psychiatric 
Disorders 
As discussed in Khandaker et al. (2015) [189], a possible link between schizophrenia, 
the immune system, and infections was postulated over a century ago. Epidemiological 
and genetic studies suggested links with infection and inflammation [189]. In recent dec-
ades, experimental and diagnostic studies have indicated complex interactions between 
the immune system, inflammation, brain functions, and behavior. Here, we hypothesize 
that the dysfunction of vasculature systems and aberrant immunity may cause severe be-
havioral characteristics and dysfunction of neurons, astrocytes, and oligodendrocytes 
(Figure 4). The dysfunction would induce the malfunctions, exemplified hyper-, and 
hypo-connection of brain functional connectivity [118]. Such an idea is not new and has 
already been provided by other studies [192–194]. However, it did not advance because 
the brain lymphatic systems were not well-known at the time. In this last section, we de-
scribe some of the vital evidence of research regarding aberrant immune response in var-
ious types of psychiatric disorders and possibly related vascular dysfunctions that re-
searchers in this field and psychiatric clinicians might be interested in. 
In the past clinical investigations of schizophrenic patients showed no differences 
from the normal young males for cerebral blood flow and oxygen consumption [195]. 
However, in the late 20th century, cerebral metabolic hypofrontality, a state of decreased 
cerebral blood flow (CBF), has been found in schizophrenia patients, as well as MDD 
[196]. It gives an assumption that both the utilization of glucose and blood flow in the 
prefrontal cortex is reduced in those psychiatric disorders. Following studies showed the 
CBF changes in the cingulate cortex, thalamus, basal ganglia, and cerebellum in schizo-
phrenic patients [197–199]. Since the end of the 20th century, researchers have also noticed 
the increase and decrease in the number of immune cells and inflammatory cytokines. For 
instance, ASD, schizophrenia, and MDD are relevant to the anomaly in their immunity 
[200,201]. In ASD patients, the blood plasma cytokine levels of IL-1b, IL-2, IL-6, IL-8, and 
TNF-a are all increased [200,202,203]. In a mouse model of ASD, an increase in the inflam-
matory cytokines (: IL-6, IL-12p40, CXCL10, CCL2, 3, and 4) have been correlated with the 
frequency or extent of the autistic-like behavior [204]. Maternal immune activation (MIA) 
in mice also shows ASD-related behaviors, representing infection-mediated neurodevel-
opmental disorders. A recent study showed the behavioral anomaly of MIA offspring is 
dependent on the IL-17a pathway [205]. The significance of the increased IL-6 signaling 
in MDD has also been discussed elsewhere [201,206]. Patients with BD show high levels 
of soluble IL-6 receptors and TNF receptors in serum samples [207], and the levels of pro-
inflammatory cytokines have been correlated to the reduction of gray matter volume 
[207]. Maternal inflammation during the third trimester of pregnancy increased the 
plasma concentration of IL-6, TNF-α, and CCL2, and the rate of the attention-deficit hy-
peractivity disorder of the birthed children [208]. Thus, many current studies suggest the 
risk of aberrant immunity on the emergence of psychosis symptoms. Furthermore, an an-
alytical study by Taoka et al. (2017) [209] suggested the impairment of the glymphatic 
system in AD using diffusion tensor image analysis [209]. The breakdown and disruption 
of brain immune-vascular systems are now investigated in the AD and ALS [83,84,90,146], 
although studies on other types of psychosis in animal models and human patients are 
expected to follow. Variability in psychiatric disorders also comes from genes and other 
intrinsic factors. Those complex factors may decide the specific vulnerability in each brain 
region and the resultant behavioral anomaly [31]. We also discussed the infiltration of 
immune cells into the brain parenchyma and the physiological disruption of neurons and 
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glia in an earlier section. This schema could be implicated in the infected or post-infected 
brain. 
3. Conclusions 
Aberrant immunity of the brain parenchyma appears to be implicated in the disrup-
tion of normal neurophysiology and brain function, which can lead to changes in mood, 
cognition, behavior, and thought throughout life; in the course of developmental stages, 
in aged brains, and in the disease conditions [11,31,210]. Inflammatory cytokines released 
from the immune cells are received via receptors of neurons in the CNS and spinal neu-
rons [161,169–172], in which the various forms of the plasticity of the efficacy of synaptic 
transmission and the intrinsic excitability of their membrane, even in the dendrites, are 
induced [118,211–214]. 
The traditional view of an immune privilege shielded by the BBB is now challenged 
by the observations of the breakdown and an increase in the immune-cell permeability 
from the blood vessels and lymphatic system at a high immune-responsive state in the 
brain, which we discussed throughout this review. These processes: infiltration of im-
mune cells into the parenchyma, the release of inflammatory cytokines, destruction of the 
glymphatic system formed by astrocytes, breakdown of the BBB, impairment of oligoden-
drocyte maturation and demyelination, and resultant damages or apoptotic events, are 
suggested to drive the dysfunction of the entire brain activity to cause abnormality in the 
functional connectivity, and to aggravate the psychosis symptoms. This hypothesis chal-
lenges the longstanding neuron-centric view of neurodegenerative and psychiatric dis-
eases and agrees with the gliocentric view [11,167]. However, we are not yet able to an-
swer the points below: When is immune privilege established and become sound? Where 
are the vulnerable areas of the brain prone to neurophysiological dysfunction? (This 
should be related to why various types of symptoms emerge in psychiatric diseases and 
why different types of diseases share the symptoms.) Is there any relevance to metabolism 
in the brain? What is the relevance to entire brain dysfunction as functional hyper- and 
hypo-connectivity? How much is transcriptome and proteome data useful for under-
standing such physiological destructions? How can we develop treatments to prevent or 
cure the progression of psychotic symptoms? Therefore, our efforts to tackle these ques-
tions should enable us to overcome the symptoms. 
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